PMGC HOLDINGS INC. Marketing Expense
PMGC HOLDINGS INC. (ELAB) reported Marketing Expense of $134.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingExpense · last filed 2024-11-14
- PMGC HOLDINGS INC. marketing expense for the quarter ending 2024-09-30 was $41.09K, a 30.59% increase year-over-year.
- PMGC HOLDINGS INC. marketing expense for the quarter ending 2024-06-30 was $43.92K, a 0.61% increase year-over-year.
- PMGC HOLDINGS INC. marketing expense for the quarter ending 2024-03-31 was $48.99K, a 132.53% increase year-over-year.
- PMGC HOLDINGS INC. marketing expense for the quarter ending 2023-09-30 was $31.47K.
| Period end | Marketing Expense 3 month | Marketing Expense 6 month | Marketing Expense 9 month |
|---|---|---|---|
| 2024-09-30 | $41.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $85.01K derived: sum of 2 quarters · filed 2024-11-14 | $134.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $43.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $92.91K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $48.99K 10-Q · filed 2024-05-15 | ||
| 2023-09-30 | $31.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $75.12K derived: sum of 2 quarters · filed 2024-11-14 | $96.18K 10-Q · filed 2024-11-14 |
| 2023-06-30 | $43.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $64.72K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $21.07K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |